1Y Close · As of Aug 26, 2026
Genexine operates in the Professional Services sector.
Legal name: Genexine, Inc.
In fiscal year 2023, Genexine (095700) reported revenue of 4.4 billion KRW, down 72.6% from 16.1 billion KRW a year earlier.
Operating profit was -41.2 billion KRW and net income was -66.9 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 134.3 billion KRW, with a P/B of 0.54.
These figures can be verified in the DART filing (receipt no. 20260311003776).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2023 | 4.4B | -41.2B | -66.9B |
| 2022 | 16.1B | -33.7B | -56.8B |
| 2021 | 36.8B | -19.4B | -48.9B |
Recent Filings
Stock Option Grant Report
투자판단관련주요경영사항 (GXI7 관련 마일스톤 기술료 청구)
Semi-Annual Report (2026.06)
Checks
3 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-24 | Stock Option Grant Report |
| 2026-08-21 | 투자판단관련주요경영사항 (GXI7 관련 마일스톤 기술료 청구) |
| 2026-08-13 | Semi-Annual Report (2026.06) |